GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Medicines Corp Ltd (SHSE:600511) » Definitions » Beneish M-Score

China National Medicines (SHSE:600511) Beneish M-Score : -2.33 (As of May. 11, 2024)


View and export this data going back to 2002. Start your Free Trial

What is China National Medicines Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for China National Medicines's Beneish M-Score or its related term are showing as below:

SHSE:600511' s Beneish M-Score Range Over the Past 10 Years
Min: -2.92   Med: -2.27   Max: -0.57
Current: -2.33

During the past 13 years, the highest Beneish M-Score of China National Medicines was -0.57. The lowest was -2.92. And the median was -2.27.


China National Medicines Beneish M-Score Historical Data

The historical data trend for China National Medicines's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Medicines Beneish M-Score Chart

China National Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.35 -2.32 -2.34 -2.58 -2.49

China National Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.51 -2.35 -2.48 -2.49 -2.33

Competitive Comparison of China National Medicines's Beneish M-Score

For the Medical Distribution subindustry, China National Medicines's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Medicines's Beneish M-Score Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Medicines's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where China National Medicines's Beneish M-Score falls into.



China National Medicines Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of China National Medicines for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9614+0.528 * 1.0841+0.404 * 1.0154+0.892 * 1.1079+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8438+4.679 * 0.001208-0.327 * 0.9943
=-2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥14,816 Mil.
Revenue was 12122.143 + 13166.379 + 12389.491 + 12913.874 = ¥50,592 Mil.
Gross Profit was 852.087 + 1163.68 + 961.559 + 1001.54 = ¥3,979 Mil.
Total Current Assets was ¥28,551 Mil.
Total Assets was ¥32,919 Mil.
Property, Plant and Equipment(Net PPE) was ¥906 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥992 Mil.
Total Current Liabilities was ¥13,733 Mil.
Long-Term Debt & Capital Lease Obligation was ¥282 Mil.
Net Income was 459.455 + 683.703 + 477.713 + 570.174 = ¥2,191 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -1719.799 + 2717.435 + 175.279 + 978.36 = ¥2,151 Mil.
Total Receivables was ¥13,909 Mil.
Revenue was 11226.302 + 10956.054 + 12536.04 + 10946.39 = ¥45,665 Mil.
Gross Profit was 864.491 + 1015.759 + 1088.417 + 924.78 = ¥3,893 Mil.
Total Current Assets was ¥26,044 Mil.
Total Assets was ¥29,973 Mil.
Property, Plant and Equipment(Net PPE) was ¥824 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,061 Mil.
Total Current Liabilities was ¥12,677 Mil.
Long-Term Debt & Capital Lease Obligation was ¥158 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(14815.672 / 50591.887) / (13909.143 / 45664.786)
=0.292847 / 0.304592
=0.9614

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3893.447 / 45664.786) / (3978.866 / 50591.887)
=0.085261 / 0.078646
=1.0841

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (28551.197 + 905.554) / 32919.056) / (1 - (26044.106 + 824.349) / 29973.102)
=0.105176 / 0.103581
=1.0154

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=50591.887 / 45664.786
=1.1079

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 824.349)) / (0 / (0 + 905.554))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(991.5 / 50591.887) / (1060.66 / 45664.786)
=0.019598 / 0.023227
=0.8438

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((282.174 + 13732.763) / 32919.056) / ((157.52 + 12676.622) / 29973.102)
=0.425739 / 0.428189
=0.9943

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2191.045 - 0 - 2151.275) / 32919.056
=0.001208

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

China National Medicines has a M-score of -2.33 suggests that the company is unlikely to be a manipulator.


China National Medicines Beneish M-Score Related Terms

Thank you for viewing the detailed overview of China National Medicines's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Medicines (SHSE:600511) Business Description

Traded in Other Exchanges
N/A
Address
No. 12 A, Sanyuan West Lane, Yongwai, Chongwen District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company is also engaged in proprietary Chinese medicines, Chinese medicine decoction pieces, Chinese medicinal materials, chemical preparations, chemical raw materials, antibiotics, and biochemical drugs.

China National Medicines (SHSE:600511) Headlines

No Headlines